Osiris touts new Prochymal data; Onyx's carfilzomib goes head-to-head with Velcade; NPS gives up long-term royalties for near-term cash;

 @FierceBiotech: Which biotech will be the next to get swept away in the M&A wave? More | Follow @FierceBiotech

@JohnCFierce: Bloomberg counts 5 $1B-plus buyouts so far this year, trending up. Also, some data I've seen suggests licensing $$ shrinking. More | Follow @JohnCFierce

 @RyanMFierce: Google's new cloud platform attracts biotech players, could rival Amazon EC2 in pharma. More | Follow @RyanMFierce

> Osiris ($OSIR) is back touting new data on its stem cell therapy Prochymal, claiming the treatment eased cardio problems for heart patients. Not all analysts, though, were happy with the data, noting that the Osiris release doesn't actually spell out how the treatment performed relative to primary or secondary endpoints. Release

> Onyx ($ONXX) is launching a late-stage, head-to-head study comparing carfilzomib with Velcade. Release

> NPS Pharmaceuticals is giving up a future royalty stream in favor of more near-term cash. After reconfiguring its deal with Amgen ($AMGN) on sales of Sensipar, NPS says it will get a $25 million payment now and accelerated payments of $50 million more. In exchange NPS is giving up royalties on the drug earned after 2018. Sensipar is used to treat secondary hyperparathyroidism. More

> Actelion ($ATLN) announced that the FDA approved their supplemental new drug application for second generation Veletri for the treatment of pulmonary arterial hypertension. Release

> Nabi Biopharmaceuticals is buying back $23 million in stock through a self-tender offer. Story

Pharma News

@FiercePharma: Glaxo will be our new No. 1 in the Top 10 Pharma Settlements special report. More | Follow @FiercePharma

> Icahn crony could profit off a seat on Forest board. Story

> GSK's Zofran arrhythmia risk leads to new label change. Item

> Bristol-Myers, AZ aim for diabetes glory with Amylin buy. News

Medical Device News